v3.26.1
SEGMENT REPORTING (Tables)
6 Months Ended
Jun. 30, 2026
SEGMENT REPORTING  
Schedule of Additional disaggregated significant segment expenses

Three Months Ended June 30

Six Months Ended June 30

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

R&D Employee Expenses

$

1,961

 

$

1,639

 

$

4,026

 

$

3,356

R&D Clinical Trial Expenses

1,955

 

1,605

3,167

 

2,641

R&D Manufacturing

766

356

1,595

832

R&D License Fees

1

1

438

G&A Professional Fees

1,537

2,045

2,694

3,002

G&A Employee Expenses

568

472

1,169

974

G&A Insurance and other

408

465

 

804

894

Other Segment Items *

(176)

 

(248)

 

(386)

 

(471)

Segment Loss

$

7,020

 

$

6,334

$

13,070

 

$

11,666

* - Other Segment Items included in net loss include finance income.